Project Grant K08NS133286

Award Date 7/15/24
Completion Date 6/30/29
Dollars Obligated $231K
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This Project Grant award of $414,191 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research by Drexel University investigating the relationship between structural variations in alpha-synuclein (α-syn) protein fibrils and the development of distinct neurodegenerative synucleinopathies such as Lewy body dementia, Parkinson's disease, and multiple system atrophy....
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to determine changes in synaptic vesicle-binding of alpha-synuclein as an early biomarker for Parkinson's disease and Alzheimer's disease related dementias. The $793,535 award to Weill Medical College of Cornell University aims to: 1) identify the gastrointestinal area...
This $2,192,716 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) aims to understand the role of serine-129 phosphorylation in the aggregation and spreading of α-synuclein pathology associated with Parkinson's disease, dementia with Lewy bodies, and related synucleinopathies. The project leverages novel serine-129 phospho-deficient and...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $246,248 to The Trustees of the University of Pennsylvania to investigate how disrupted autophagy contributes to the chronic inflammation and plaque formation associated with the progression of Alzheimer's disease (AD) and related dementias. The researcher will use AD risk variants...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to establish the role of alpha-synuclein-mediated membrane permeabilization in the spread of alpha-synuclein aggregates related to Parkinson's disease and related dementias. The $406,260 award to Purdue University will leverage fluorescence lifetime imaging microscopy...
This federal Project Grant award for $858,471.00, awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research focused on understanding the role of N-terminal acetylation in alpha-synuclein stability, function, and therapeutic targeting for Parkinson's disease and related neurodegenerative disorders. The key objectives are to: 1) Identify the molecular...
This Project Grant award, valued at $716,000.00 and issued by the National Institute on Aging (CFDA 93.866 Aging Research) on August 15, 2024, supports research to distinguish between physiological and pathological phosphorylation of alpha-synuclein (α-synuclein) at serine 129 (PS129) in Parkinson's disease (PD), Parkinson's disease with dementia (PDD), and dementia with Lewy bodies (DLB). The research aims to: 1) Compare the biochemical properties of physiological and pathological PS129, and 2)...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to investigate the role of the GPNMB gene in the pathogenesis of Parkinson's disease, Lewy body dementia, and related synucleinopathies. The $655,329 award to the Albert Einstein College of Medicine aims to identify causal genetic variants that regulate GPNMB expression...
This Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to investigate the role of synaptic organizers in Parkinson's disease pathology and potential therapeutic interventions. The total funding amount is $669,115, awarded on September 1, 2024 with a project period ending on August 31, 2029. The research project, led by Texas A&M...
This three-year, $3.4 million Project Grant from the National Institute on Aging will support research into the combinatorial effects of post-translational modifications on alpha-synuclein structure, function, and aggregation. The Trustees of the University of Pennsylvania will investigate how multiple simultaneous modifications to alpha-synuclein impact its interactions with lipid bilayers, self-association kinetics, aggregate structural features, internalization by neurons, and seeded...

DETERMINING THE ORIGIN AND PATHOGENICITY OF PLASMA-DERIVED ALPHA-SYNUCLEINSTRAINS - PROJECT SUMMARY/ABSTRACT PARKINSON'S DISEASE (PD) IS THE SECOND MOST COMMON NEURODEGENERATIVE DISORDER AFFECTING OVER 10 MILLION PEOPLE WORLDWIDE AND CONTRIBUTES TO OVER $52 BILLION YEARLY IN US HEALTHCARE COSTS. DESPITE INVESTIGATION INTO MECHANISMS OF A-SYNUCLEIN (ASYN) MISFOLDING AND AGGREGATION LEADING TO NEURONAL DYSFUNCTION AND DEATH, THE INCITING EVENTS OF THE HALLMARK OF PD PATHOLOGY IN HUMANS ARE NOT UNDERSTOOD. THE SYSTEMIC MANIFESTATIONS OF PD HAVE LED TO THE DISCOVERY OF ASYN PATHOLOGY IN MULTIPLE PERIPHERAL TISSUES, INCLUDING PLASMA. UNDERSTANDING THE ORIGIN OF PERIPHERAL ASYN PATHOLOGY IS CRITICAL TO ADVANCING THE UNDERSTANDING OF PD AND TO DEVELOPING EARLY DISEASE-MODIFYING THERAPIES. IN PRELIMINARY WORK, ANTIBODIES GENERATED AGAINST IN VITRO STRAINS OF ASYN ARE DETECTABLE AT HIGHER LEVELS IN INDIVIDUALS WITH PD (IWPD), RELIABLY DISCRIMINATING THEM FROM INDIVIDUALS WITH DEMENTIA WITH LEWY BODIES, WHEN NO OTHER DIFFERENTIATING BIOMARKERS EXISTS FURTHERMORE, ONE OF THESE ASYN STRAINS IS ELEVATED IN PLASMA FROM IWPD WHO HAVE A REDUCED RATE OF COGNITIVE DECLINE. THESE STRAINS ARE NOT RELIABLY DETECTED IN CEREBROSPINAL FLUID AND DO NOT CORRELATE WITH LEVELS OF STRAIN-SPECIFIC ASYN FOUND IN WHITE OR RED BLOOD CELLS IMPLICATING AN ALTERNATIVE PERIPHERAL TISSUE SOURCE. THE GOALS OF THIS PROPOSAL ARE 1) TO USE EXTRACELLULAR VESICLES, MEMBRANE-BOUND STRUCTURES SECRETED BY CELLS, TO IDENTIFY THE TISSUE SOURCE OF PLASMA ASYN STRAINS IN AN UNBIASED MANNER AND 2) DETERMINE THE FUNCTIONAL AND PATHOGENIC PROPERTIES OF PLASMA ASYN STRAINS IN BIOCHEMICAL ASSAYS AND A CELLULAR MODEL OF PD. IN LINE WITH THE MISSION OF THE NINDS, THIS WORK HAS THE POTENTIAL TO IMPROVE UNDERSTANDING OF FUNDAMENTAL MECHANISMS OF PD PATHOGENESIS AND TO LEAD TO DEVELOPMENT OF TREATMENTS THAT REDUCE PD MORBIDITY. DR. GEORGE KANNARKAT IS A DRIVEN, HIGHLY QUALIFIED PHYSICIAN-SCIENTIST WHO IS CURRENTLY AN INSTRUCTOR AND PARTICIPATING IN THE "REMAPPING CLINICAL NEUROSCIENCE THROUGH TRANSLATION AND INNOVATION TRAINING" T32 TRAINING PROGRAM AT THE UNIVERSITY OF PENNSYLVANIA. HE HAS A PROVEN TRACK RECORD OF PRODUCTIVITY IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH, PARTICULARLY WITH A BACKGROUND IN PERIPHERAL AND IMMUNE MECHANISMS OF NEURODEGENERATION. THIS FIVE-YEAR MENTORED K08 AWARD INCLUDING MENTORSHIP, FORMAL AND SELF-DIRECTED TRAINING, AND A RIGOROUS RESEARCH PLAN WILL ALLOW HIM TO BROADEN HIS SKILLS IN 1) LARGE-SCALE NUCLEIC ACID AND PROTEOMICS ANALYSIS, 2) MODELS OF SYNUCLEINOPATHY, AND 3) MANIPULATION OF INDUCED PLURIPOTENT STEM-CELLS. WITH STRONG INSTITUTIONAL SUPPORT FROM THE NUMEROUS RESOURCES AT THE UNIVERSITY OF PENNSYLVANIA AND THE MENTORSHIP FROM DR. ALICE CHEN-PLOTKIN (MENTOR), A WORLD-RENOWNED EXPERT IN BIOINFORMATIC APPROACHES TO IDENTIFYING BIOMARKERS OF NEURODEGENERATION, AND HIS ADVISORY COMMITTEE, HE IS WELL-POISED TO ACHIEVE HIS GOAL OF BEING AN INDEPENDENT R01-FUNDED PHYSICIAN-SCIENTIST STUDYING THE INTERPLAY OF PERIPHERAL AND CENTRAL MECHANISMS, SUCH AS INFLAMMATION, ENVIRONMENTAL EXPOSURES, AND PROTEINOPATHY, LEADING TO NEURODEGENERATION

Posted 7/15/24, 12:00 AM